Pharming Group (PHARM) announced that shareholders approved all proposals at the 2026 Annual General Meeting of Shareholders held on May 28, 2026.
Approvals covered appointing KPMG Accountants as external auditor for 2026–2028, updating non-executive director remuneration, and renewing share issuance and share repurchase authorizations.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
This announcement confirms shareholder approval of all AGM proposals, including appointing KPMG as i...
Analysis
This announcement confirms shareholder approval of all AGM proposals, including appointing KPMG as independent external auditor for 2026–2028, amending the Board’s remuneration policy, and renewing authorizations to issue and repurchase shares. These items provide governance and capital-structure flexibility but do not, by themselves, signal how that flexibility will be used. Investors may focus on future disclosures and Board decisions on share issuance, buybacks, and compensation implementation to gauge the longer-term impact.
Key Figures
Auditor term:2026-2028Agenda item:3Agenda item:4+2 more
5 metrics
Auditor term2026-2028KPMG appointed as independent external auditor
Agenda item3Appointment of independent external auditor
Agenda item4Remuneration policy amendment for Non-Executive Directors
Agenda item5Renewal of authorization to issue shares
Agenda item6Renewal of authorization to repurchase shares
"KPMG Accountants N.V. was appointed as the Company’s independent external auditor"
An independent external auditor is a neutral, third-party accounting professional or firm that examines a company’s financial records, statements, and internal controls to confirm they are accurate and comply with accounting rules. Like a referee verifying a game's score, their independent report gives investors confidence that reported results are reliable and helps reveal mistakes, misleading practices, or weaknesses that could affect the company’s financial health and investment risk.
remuneration policyfinancial
"approved the proposals to amend the Remuneration policy for the Board of Directors"
A remuneration policy is a company’s written guide on how it pays executives and senior managers, covering salary, bonuses, stock awards and other benefits. It matters to investors because it shows how pay is linked to long-term performance and risk—like a recipe that determines whether incentives encourage sustainable growth or reward short-term gains—affecting governance, shareholder returns and potential conflicts of interest.
repurchase sharesfinancial
"to renew the authorizations for the Board of Directors to issue shares and to repurchase shares"
A company buying back its own outstanding stock from the market or directly from shareholders, reducing the number of shares available to the public. For investors this matters because it can boost per-share metrics and share price by concentrating ownership and signaling management’s confidence, but it also uses cash that could be spent elsewhere—think of a store redeeming gift cards to reduce outstanding coupons and make the remaining ones effectively more valuable.
Leiden, the Netherlands, May 28, 2026: Pharming Group (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced that shareholders approved all proposals presented at its Annual General Meeting of Shareholders (AGM), held earlier today.
KPMG Accountants N.V. was appointed as the Company’s independent external auditor for the financial years 2026 through 2028 (agenda item 3).
Shareholders also approved the proposals to amend the Remuneration policy for the Board of Directors regarding the fees to be paid to the Non-Executive Directors (agenda item 4), to renew the authorizations for the Board of Directors to issue shares (agenda item 5) and to repurchase shares (agenda item 6).
A recording of the webcast, the AGM presentation slides, voting results and additional information on the agenda items are available on the Company’s website under Investors/Shareholder Meetings.
About Pharming Group N.V. Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We develop and commercialize a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with U.S. and European operations.
Inside Information This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
For further public information, contact: Investor Relations Michael Levitan, VP Investor Relations and Capital Markets T: +1 (908) 705 1696 E: investor@pharming.com
Media Relations Global: Saskia Mehring, Head of Corporate Communications T: +31 6 28 32 60 41 E: media.relations@pharming.com
U.S.: Christina Skrivan (Precision AQ on behalf of Pharming) T: +1 (636)-352-7883
Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming) T: +31 6 53 81 64 27
What did Pharming Group (PHARM) announce from its 2026 AGM on May 28, 2026?
Pharming Group reported that shareholders approved all proposals at the 2026 AGM. According to Pharming, this included auditor appointment, remuneration policy changes, and renewed authorizations to issue and repurchase shares, reflecting broad shareholder support for current governance arrangements.
Which external auditor did Pharming Group (PHARM) appoint for 2026–2028?
Pharming Group shareholders appointed KPMG Accountants N.V. as independent external auditor for financial years 2026 through 2028. According to Pharming, this auditor appointment was approved under agenda item 3 during the 2026 Annual General Meeting of Shareholders held in Leiden.
What remuneration policy changes for non-executive directors did Pharming (PHARM) approve at the 2026 AGM?
Pharming shareholders approved amendments to the Board of Directors’ remuneration policy covering fees for non-executive directors. According to Pharming, this change was addressed under agenda item 4 and focuses specifically on the structure and level of compensation for non-executive board members.
Did Pharming Group (PHARM) renew its authorization to issue shares at the 2026 AGM?
Yes, Pharming shareholders renewed the Board of Directors’ authorization to issue shares. According to Pharming, this approval came under agenda item 5 and allows the board continued flexibility to issue equity, subject to applicable limits and future strategic or financing needs.
Was a share repurchase authorization approved for Pharming Group (PHARM) in 2026?
Shareholders approved renewing Pharming’s authorization to repurchase shares. According to Pharming, this was agenda item 6 and gives the Board of Directors the ability to buy back company shares within legal and corporate limits if it considers such actions appropriate later.
Where can investors find the 2026 Pharming (PHARM) AGM voting results and webcast?
Investors can access the 2026 AGM webcast recording, presentation slides, and detailed voting results on Pharming’s website. According to Pharming, these materials are available in the Investors section under Shareholder Meetings for on-demand review after the meeting.
